本帖最后由 老马 于 2012-1-13 21:20 编辑
' {0 y3 T! |) B7 z7 z* w7 y
' D4 r* C7 e! ]" U" u1 [爱必妥和阿瓦斯丁的比较7 ^8 O: h! Q( C( |8 U! K3 j
) @' M7 T0 F- t2 d9 |2 x- ?" Dhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
) t- ]0 k% y- A# ~# M
1 n9 R. a, i( t% L. y
+ p$ n$ m4 U- V4 Y* I/ c
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/5 e1 g6 H) K2 Q2 r; D
==================================================
; Z8 u, X6 [0 n% Z QOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)) R+ M2 u3 E! t. i% r
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.5 K4 l! M& C$ N* Q
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.3 u) N! s* k1 T- N
|